Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area

Biochemical Pharmacology

Volumn 74, Issue 8, 2007, Pages 1283-1291

  Mansvelder, Huibert D ^a   Fagen, Zara M ^a   Chang, Ben ^a   Mitchum, Robert ^a   McGehee, Daniel S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acetylcholine; Dopamine; GABA; Glutamate; Nicotinic; Synaptic Transmission

Indexed keywords

AMFEBUTAMONE; DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ABUSE; GABAERGIC TRANSMISSION; NERVE CELL EXCITABILITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REWARD; STIMULATION; SYNAPTIC INHIBITION; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANIMALS; BUPROPION; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTAL AREA;

EID: 34548703154     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.034     Document Type: Article

References (53)

1. Peto R., Chen Z.M., and Boreham J. Tobacco-the growing epidemic. Nat Med 5 (1999) 15-17
2. Benowitz N.L. Nicotine addiction. Primary Care 26 (1999) 611-631
3. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
4. Helge T.D., and Denelsky G.Y. Pharmacologic aids to smoking cessation. Cleve Clin J Med 67 818 (2000) 21-24
5. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997) 1195-1202
6. Hughes J.R., Goldstein M.G., Hurt R.D., and Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 281 (1999) 72-76
7. Rauhut A.S., Dwoskin L.P., and Bardo M.T. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 7 (2005) 901-907
8. Ferris R.M., and Beaman O.J. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 22 (1983) 1257-1267
9. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 (1995) 395-401
10. Dwoskin L.P., Rauhut A.S., King-Pospisil K.A., and Bardo M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12 (2006) 178-207
11. Fryer J.D., and Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288 (1999) 88-92
12. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295 (2000) 321-327
13. Miller D.K., Sumithran S.P., and Dwoskin L.P. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther 302 (2002) 1113-1122
14. Sidhpura N., Redfern P., and Wonnacott S. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices. Eur J Pharmacol 567 (2007) 102-109
15. Corrigall W.A., Coen K.M., and Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653 (1994) 278-284
16. Nisell M., Nomikos G.G., and Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16 (1994) 36-44
17. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85 (1988) 5274-5278
18. Imperato A., Mulas A., and Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132 (1986) 337-338
19. Schilstrom B., Nomikos G.G., Nisell M., Hertel P., and Svensson T.H. N-Methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82 (1998) 781-789
20. Mansvelder H.D., and McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27 (2000) 349-357
21. Mansvelder H.D., Keath J.R., and McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33 (2002) 905-919
22. Mansvelder H.D., and McGehee D.S. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53 (2002) 606-617
23. Johnson S.W., and North R.A. Two types of neurons in the rat ventral tegmental area and their synaptic inputs. J Physiol (Lond) 450 (1992) 455-468
24. Margolis E.B., Lock H., Hjelmstad G.O., and Fields H.L. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons?. J Physiol 577 (2006) 907-924
25. Ford C.P., Mark G.P., and Williams J.T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26 (2006) 2788-2797
26. Honore T., Davies S.N., Drejer J., Fletcher E.J., Jacobsen P., Lodge D., et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 (1988) 701-703
27. Johnston G.A.R. Physiologic pharmacology of GABA and its antagonists in the vertebrate nervous system. In: Roberts E., Chase T.N., and Tower D.B. (Eds). GABA in Nervous System Function (1976), Raven Press, New York 305-317
28. Calabresi P., Lacey M.G., and North R.A. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording. Br J Pharmacol 98 (1989) 135-140
29. Pidoplichko V.I., DeBiasi M., Williams J.T., and Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390 (1997) 401-404
30. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
31. Findlay J.W., Van Wyck Fleet J., Smith P.G., Butz R.F., Hinton M.L., Blum M.R., et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21 (1981) 127-135
32. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., and Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37 (1997) 737-743
33. Johnson S.W., Seutin V., and North R.A. Burst firing in dopamine neurons induced by N-methyl-d-aspartate: role of electrogenic sodium pump. Science 258 (1992) 665-667
34. Wang. T., and French E.D. Electrophysiological evidence for the existence of NMDA and non-NMDA receptors on rat ventral tegmental dopamine neurons. Synapse 13 (1993) 270-277
35. Kalivas P.W., Churchill L., and Klitenick M.A. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57 (1993) 1047-1060
36. Westerink B.H., Kwint H.F., and deVries J.B. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16 (1996) 2605-2611
37. Yin R., and French E.D. A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an in vitro electrophysiological study. Brain Res. Bull 51 (2000) 507-514
38. Fiorillo C.D., and Williams J.T. Cholinergic inhibition of ventral midbrain dopamine neurons. J Neurosci 20 (2000) 7855-7860
39. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6 (1990) 106-112
40. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
41. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 (2005) 3474-3477
42. Siu E.C., and Tyndale R.F. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 47 (2007) 541-564
43. Wiley J.L., Lavecchia K.L., Martin B.R., and Damaj M.I. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10 (2002) 129-135
44. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 (1996) 733-736
45. Balfour D.J. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 55 (2001) 53-57
46. Alkondon M., and Albuquerque E.X. Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional upregulation by nicotine and to block by bupropion. J Pharmacol Exp Ther 313 (2005) 740-750
47. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J Neurosci 21 (2001) 1819-1829
48. Hughes J.R., Stead L.F., and Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 7 (2005) 491-499
49. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 1 (2007) 10.1002/14651858.CD000031.pub3 Art. No.: CD000031
50. Lipkus I.M., Barefoot J.C., Williams R.B., and Siegler I.C. Personality measures as predictors of smoking initiation and cessation in the UNC Alumni Heart Study. Health Psychol. 13 (1994) 149-155
51. Hayford K.E., Patten C.A., Rummans T.A., Schroeder D.R., Offord K.P., Croghan I.T., et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174 (1999) 173-178
52. Paterson N.E., Balfour D.J., and Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25 (2007) 3099-3108
53. DiFranza J.R., Rigotti N.A., McNeill A.D., Ockene J.K., Savageau J.A., Cyr D.S., et al. Initial symptoms of nicotine dependence in adolescents. Tob Control 9 (2000) 313-319